These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 28378227)
21. Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy. Claes B; Buysschaert I; Lambrechts D Heredity (Edinb); 2010 Jul; 105(1):152-60. PubMed ID: 20389307 [TBL] [Abstract][Full Text] [Related]
22. Targeting epigenetics for the treatment of prostate cancer: recent progress and future directions. Lin J; Wang C; Kelly WK Semin Oncol; 2013 Jun; 40(3):393-401. PubMed ID: 23806502 [TBL] [Abstract][Full Text] [Related]
23. Role of the tumor stroma in resistance to anti-angiogenic therapy. Huijbers EJ; van Beijnum JR; Thijssen VL; Sabrkhany S; Nowak-Sliwinska P; Griffioen AW Drug Resist Updat; 2016 Mar; 25():26-37. PubMed ID: 27155374 [TBL] [Abstract][Full Text] [Related]
24. Epigenetics and oncology. Mummaneni P; Shord SS Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798 [TBL] [Abstract][Full Text] [Related]
28. Epigenetic therapy of cancer with histone deacetylase inhibitors. Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724 [TBL] [Abstract][Full Text] [Related]
29. Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. Stazi G; Fioravanti R; Mai A; Mattevi A; Valente S Curr Opin Chem Biol; 2019 Jun; 50():89-100. PubMed ID: 30986654 [TBL] [Abstract][Full Text] [Related]
30. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors. Kumar A; Emdad L; Fisher PB; Das SK Adv Cancer Res; 2023; 158():73-161. PubMed ID: 36990539 [TBL] [Abstract][Full Text] [Related]
31. [Development of HDAC inhibitors]. Sowa Y Gan To Kagaku Ryoho; 2010 Sep; 37(9):1665-8. PubMed ID: 20841929 [TBL] [Abstract][Full Text] [Related]
32. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy. Zahnow CA; Topper M; Stone M; Murray-Stewart T; Li H; Baylin SB; Casero RA Adv Cancer Res; 2016; 130():55-111. PubMed ID: 27037751 [TBL] [Abstract][Full Text] [Related]
33. [Targeted epigenetic therapy of cancer. Achievements and perspectives]. Valdespino-Gómez VM; Valdespino-Castillo VE Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455 [TBL] [Abstract][Full Text] [Related]
34. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Lu Y; Chan YT; Tan HY; Li S; Wang N; Feng Y Mol Cancer; 2020 Apr; 19(1):79. PubMed ID: 32340605 [TBL] [Abstract][Full Text] [Related]
35. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target? Petta V; Gkiozos I; Strimpakos A; Syrigos K Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844 [TBL] [Abstract][Full Text] [Related]
36. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy. Rondelet G; Wouters J Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135 [TBL] [Abstract][Full Text] [Related]
38. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Cao Y Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094 [TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies. Markozashvili D; Ribrag V; Vassetzky YS Invest New Drugs; 2015 Dec; 33(6):1280-91. PubMed ID: 26423245 [TBL] [Abstract][Full Text] [Related]
40. Promising strategies: Combination of epigenetic inhibitors for cancer therapy. Gronemeyer H Int J Cancer; 2020 Nov; 147(10):2656-2657. PubMed ID: 32599650 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]